<DOC>
	<DOCNO>NCT01831037</DOCNO>
	<brief_summary>This study aim demonstrate patient chronic hepatitis C ( CHC ) B ( CHB ) experience regression liver cirrhosis effective antiviral therapy decrease risk hepatocellular carcinoma ( HCC ) . Primary aim determine incidence HCC patient cirrhosis secondary CHC CHB , treatment provide , identify magnitude decrease risk HCC patient experience regression fibrosis . As secondary aim , environmental risk factor HCC development seek , order determine subset patient safe stop surveillance .</brief_summary>
	<brief_title>The Regression Liver Fibrosis Risk Hepatocellular Carcinoma ( ROLFH ) Study</brief_title>
	<detailed_description>Cirrhosis final pathway chronic liver disease , 30 % patient develop hepatocellular carcinoma ( HCC ) within 5 year diagnosis cirrhosis . Worldwide , chronic hepatitis C ( CHC ) B ( CHB ) account majority case cirrhosis . Successful antiviral treatment result regression fibrosis majority patient . Surveillance program early detection HCC mandate use imaging ( ultrasound/CT-scan ) every 6 month . It show CHC CHB risk HCC greatly reduce viral disease eradicated/inactive . However , impact regression fibrosis factor could abate incidence HCC systematically investigate . Currently , patient eradicated/inactive viral disease continue enrol HCC surveillance program , generate anxiety patient high cost healthcare system . Fibrotest ( FT ) transient elastography ( TE ) noninvasive tool proven useful serial assessment liver fibrosis . OBJECTIVES : The propose hypothesis patient regression liver fibrosis decrease risk HCC . Primary aim determine incidence HCC patient cirrhosis secondary CHC CHB , 3-7 year treatment provide , identify magnitude decrease risk HCC patient experience regression fibrosis . As secondary aim , environmental risk factor HCC development seek , order determine subset patient safe stop surveillance . METHODS : Patients 18-70 year-old cirrhosis identify hepatology clinic 4 academic center North America . FT/TE obtain start antiviral yearly thereafter ( prospective arm ) . A retrolective arm patient treat earlier Jan/2009 also include . In group , baseline FT/TE perform treatment ( CHC ) initial phase therapy ( CHB ) , yearly thereafter . During baseline yearly visit factor possibly affect HCC development investigate ( family history , comorbidities , BMI , diet , etc. ) . Patients classify undergone regression fibrosis 3-year follow , depend FT TE evolution . During follow , patient undergo 6-month imaging part routine HCC surveillance . Based power calculation , enrollment stop 924 patient recruit . Kaplan-Meier Cox regression model use analyze data . PATIENT OUTCOMES : ROLFH study use state-of-the-art noninvasive marker liver fibrosis test whether reverse fibrosis decrease risk HCC . We believe study lead well understanding HCC risk factor , improve patient counsel decision making , optimize screen allocation health resource , decrease healthcare cost .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Age 1870 Chronic liver disease due CHC CHB . Starting diseasespecific treatment earlier January 2010 . Treatment could consist : combination therapy peginterferon ribavirin , without directacting viral agent CHC ; single combination therapy contain peginterferon , entecavir , tenofovir CHB . Established cirrhosis liver biopsy ( METAVIR F4 ) obtain start diseasespecific treatment . In patient without liver biopsy , follow criterion use surrogate define cirrhosis : History spleen &gt; 13 cm , bilirubin &gt; 2 , albumin &lt; 3.5 , INR &gt; 1.5 ( 2 3 criterion ) . History APRI ( [ AST/ULN ] /platelets x 100 ) &gt; 2 , esophageal varix ascites . History Fibrotest/Fibrosure &gt; 0.74 , TE &gt; 12.5 kPa ( Mprobe ) &gt; 10 kPa ( XLprobe ) . Known diagnosis hepatocellular carcinoma portal vein thrombosis Conditions limiting Fibrotest/Fibrosure read : hemolysis , Gilbert 's syndrome , autoimmune disease . Conditions limit TE read : ascites , heart failure retrograde vascular congestion , extrahepatic cholestasis . Pregnancy implantable active medical device ( pacemaker defibrillator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Regressed cirrhosis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Noninvasive marker fibrosis</keyword>
	<keyword>FibroTest</keyword>
	<keyword>FibroSure</keyword>
	<keyword>FibroScan</keyword>
	<keyword>Transient elastography</keyword>
</DOC>